CSL vs GSK vs Pfizer and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: CSL 3.6525, GSK 10.595, Pfizer 15.034, Merck & Co. 16.607.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, CSL, GSK, Pfizer, Merck & Co..| Metric | CSL | GSK | Pfizer | Merck & Co. |
|---|---|---|---|---|
| Market Cap | $56.82B | $105.97B | $161.04B | $375.58B |
| Revenue | $7.30B | $10.60B | $15.03B | $16.61B |
| Cost of Revenue | $4.06B | $2.85B | $4.09B | $4.39B |
| Gross Profit | $3.24B | $7.74B | $10.94B | $12.21B |
| Operating Income | $1.39B | $606.00M | $4.71B | $-683.00M |
| Net Income | $-2.94B | $548.00M | $-246.00M | $-1.33B |
| R&D Expense | $614.00M | $4.37B | $2.81B | $9.74B |
| Earnings Per Share | -$6.14 | $0.28 | -$0.04 | -$0.54 |
| Gross Margin | 44.4% | 73.0% | 72.8% | 73.5% |
| Operating Margin | 19.0% | 5.7% | 31.3% | -4.1% |
| Net Profit Margin | -40.2% | 5.2% | -1.6% | -8.0% |
| Free Cash Flow | $1.76B | $2.78B | $302.00M | $4.48B |
| Cumulative Free Cash Flow | $21.56B | $157.21B | $356.70B | $249.70B |
| Operating Cash Flow | $2.09B | $3.19B | $835.00M | $5.37B |
| Cash & Equivalents | $1.51B | $3.89B | $976.00M | $6.85B |